Spyre Therapeutics (SYRE) announced that it has initiated dosing in a healthy volunteer, Phase 1 clinical trial of its investigational half-life extended anti-IL-23 monoclonal antibody, SPY003. This milestone marks our fourth on-time clinical trial initiation in nine months.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Strategic Potential of Spyre Therapeutics in Combination Therapies for Inflammatory Diseases
- Spyre Therapeutics initiated with an Outperform at Wolfe Research
- Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status
- Buy Rating for Spyre Therapeutics: Promising Pipeline and Strategic Advancements Drive Growth Potential
- Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position